A. Anticoagulant drugs §1. Pharmacological effects §(1) Anticoagulation Increasing the activity of AT III: The AT III inhibiting the activity of the activated XIIa, XI, Xa, IXa, Ⅶ a, IIa, etc. § Rapid and short (2~4 h) § Effective both in vitro and in vivo §(2) Anti –atherosclerosis § blood lipids § protecting endothelial cells § inhibiting the hypertrophy of smooth muscle cells §(3) Other effects: § Antiinflammatory, antioxydant effects, etc.
A. Anticoagulant drugs §1. Pharmacological effects §(1) Mechanisms of action: § antagonizing vitamine K, inhibiting of carboxylation of the glutamic acid residues of the factors II, VII, IX, X, and inducing the activated II, VII, IX, X §(2) Properties: § slowly and longer duration: effect appears after p.o. 1~3 days, and lasts for 4 days § effective only in vivo
A. Anticoagulant drugs §2. Clinical uses Anticoagulation in vivo § Anticoagulation in vivo §3. Adverse effects §(1) Bleeding: v itamine K may antagonite the reaction; Interrelaction with other agents (2) Necrosis of skin and parenchyma ( 软组织 ) §(3) Liver injury
4. Drug interactions Plasma protein binding replacement Hepatic metabolism: inhibition inhibition stimulation stimulation
D. Drugs for treatment of bleeding Vitamine K § Vitamine K §Carboxylation of the glutamic acid residues of factors II, IIV, IX, X, protein C. §Preventing bleeding with vitamine K deficiency or warfarin-induced bleeding
D. Drugs for treatment of bleeding §Thrombin-like agents thrombin, § thrombin, § prothrombin complex, § § used for various bleeding
D. Drugs for treatment of bleeding §Drugs preventing activation of antifibrinolytics § aprotinin, § tranexamic acid (AMCHA, 氨甲环酸 ) § p-aminomethylbenzoic acide (PAMBA, 氨 甲苯酸） used forpreventing the activation fibrinolysis and resultant bleeding § used for preventing the activation fibrinolysis and resultant bleeding
E. Drugs for treatment of anemia §Anemia may result from the excess destruction of erythrocytes, and nutritional deficiencies (iron, minerals, cobalt, vitamin B 12, folic acid, ascorbic acid, riboflavin, copper, zinc, etc. §Iron: § anemia due to loss of erythrocytes and iron deficiency §Folic acid and vitamin B 12 : § megaloblastic anemia §Erythropoietin (EPO) § promoting red cell proliferation and differetiation
E. Drugs for treatment of anemia §Iron ferrous sulfate 硫酸亚铁 ferric ammonium citrate 枸橼酸铁铵 § 1. Interaction with other drugs or diet in the GI tract §2. Used for anemia due to loss of erythrocytes and iron deficiency §3. Adverse effects: GI reactions, hypersensitivity §Acute intoxication: severe CNS, GI reactions §- treated with deferoxamine （去铁敏）
Folic acid metabolism and the effect of vitamin B 12
E. Drugs for treatment of anemia §Erythropoietin (EPO) § rhEPO §1. Pharmacological effects §promoting red cell proliferation and differetiation §2. Clinical uses §Anemia due to chronic renal failure with hemodialysis, radiotherapy, chemotherapy, AIDS, etc. §3. Adverse effects §Hypertension, epilepsy, thrombosis, etc.
Effect of EPO on red cell proliferation and differentiation
F. Hematopoietic growth agents §Granulaocyte colony-stimulating factor G-CSF 粒细胞集落刺激因子 §Granulaocyte/macrophage colony-stimulating factor GM-CSF 粒细胞 / 巨噬细胞集落刺激因子 §Used for neutropenia (chemotheapy or radiotherapy), autologous bone marrow transplantation, myelodysplasia, aplastic anemia, AIDS-associated neutropenia §Allergy, GI and hepatic injuries, local irritation, etc.